JNJ 10229570 AAA

Drug Profile

JNJ 10229570 AAA

Alternative Names: JNJ-10229570; JNJ-10229570-AAA; MC 5 - Ortho Dermatologics; MC5-RA - Ortho Dermatologics

Latest Information Update: 02 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ortho Dermatologics
  • Developer Valeant Pharmaceuticals International
  • Class Antiacnes
  • Mechanism of Action Melanocortin type 5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acne vulgaris

Most Recent Events

  • 27 Jul 2017 Valeant Pharmaceuticals International acquired Ortho Dermatologics in 2011 and changed the name of the later to Valeant Dermatology. Subsequently, in July 2017, it was rebranded to Ortho Dermatologics
  • 12 Dec 2011 Valeant Pharmaceuticals acquires Ortho Dermatologics
  • 29 Nov 2011 Johnson and Johnson completes enrolment in its phase II trial for Acne vulgaris in USA (NCT01326780)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top